A Pilot Study of Ocrelizumab Infusion Reaction Rates Among Multiple Sclerosis Patients Treated in a Hospital and 2 Outpatient Sites of Care
Infusion Journal · 2022
DOI: 10.70776/knob7854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infusion Journal, 2022. Verfasst von Sofia Shrestha und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Economic data on site of care optimization is well-established, yet limited data exist on the safety of administering ocrelizumab in home infusion settings. Ocrelizumab is administered for the treatment of multiple sclerosis and carries a warning for the risk of infusion-related reactions (IRRs) during administration. The study objective was to measure the incidence and severity of infusion-related reactions in patients receiving ocrelizumab administered in both hospital-based and outpatient sites of care.
Methods
This was a retrospective study of patients who received ocrelizumab infusions for multiple sclerosis between March 2017 and September 2019. Patient and infusion characteristics were compared by infusion setting using appropriate nonparametric tests and z-tests.
Results
There were 85 patients with 230 ocrelizumab infusions. Patients were similar demographically. Outpatient sites of care had a higher proportion of maintenance infusions than hospital-based sites of care (outpatient: 81.1%, hospital: 43.0%, p=0.0001). There were 25 IRRs reported, a majority of these in the hospital setting (92.0%), with encounter rates similar across infusion settings (outpatient: 5.4%, hospital: 11.9%; p=0.24).
Conclusion
This study demonstrated similar incidence, severity, and management of ocrelizumab IRRs regardless of infusion setting. Although limited by the small sample size, safety results endorse clinical support for administering ocrelizumab in outpatient sites of care. Patient access to ocrelizumab infusions in their home or ambulatory infusion suite may improve adherence to the medication therapy and improve disease outcomes. Keywords: infused specialty medication, home infusion, infusion site of care (SOC), safety outcomes, infusion-related reaction (IRR) Key Points: Site of care optimization as a utilization management strategy encourages the use of lower-cost, convenient care settings, however, data on real-word utilization and clinical outcomes is limited. This retrospective pilot study demonstrated that infusion-related reactions from ocrelizumab are infrequent and mild. Current data supports the safe and cost-effective administration of ocrelizumab in an outpatient, ambulatory, or home infusion setting
Zitieren
APA
Shrestha, S., Simonson, D., & Zagel, A. (2022). A Pilot Study of Ocrelizumab Infusion Reaction Rates Among Multiple Sclerosis Patients Treated in a Hospital and 2 Outpatient Sites of Care. Infusion Journal. https://doi.org/10.70776/knob7854
Vancouver
Shrestha S, Simonson D, Zagel A. A Pilot Study of Ocrelizumab Infusion Reaction Rates Among Multiple Sclerosis Patients Treated in a Hospital and 2 Outpatient Sites of Care. Infusion Journal. 2022. doi:10.70776/knob7854
BibTeX
@article{Shrestha2022,
author = {Shrestha, Sofia and Simonson, Dana and Zagel, Alicia},
title = {A Pilot Study of Ocrelizumab Infusion Reaction Rates Among Multiple Sclerosis Patients Treated in a Hospital and 2 Outpatient Sites of Care},
journal = {Infusion Journal},
year = {2022},
doi = {10.70776/knob7854}
}
EUVIMED